16
total announcements
AJOONI.NS · 15 min delayed
Ajooni Biotech Limited
Ajooni Biotech Limited has submitted its un-audited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 43.18 lakhs and a basic EPS of Rs. 0.01.
Ajooni Biotech Limited
Ajooni Biotech Limited has submitted its financial results for the period ended June 30, 2026.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange regarding allotment of 90,00,000 equity shares at ₹4.30 each to Healthy Biosciences Limited through a preferential issue.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, where the members have approved the increase in Authorised Share Capital and Amendment of Capital Clause of the Memorandum of Association.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange about the re-appointment of Mr. Gursimran Singh as Director who retires by rotation, as approved by the 16th Annual General Meeting of the company.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange about the issuance of 90,00,000 equity shares on a preferential basis, approved by the members at the 16th Annual General Meeting.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange about an increase in its authorized capital from Rs. 35,00,00,000 to Rs. 70,00,00,000, with the number of equity shares increasing from 17,50,00,000 to 35,00,00,000, following approval at its 16th Annual General Meeting.
Ajooni Biotech Limited
Ajooni Biotech Limited has submitted the Exchange a copy of the Scrutinizer's report of the 16th Annual General Meeting held on July 29, 2026, and informed the Exchange regarding voting results. All four resolutions were passed with the requisite majority.
Ajooni Biotech Limited
Ajooni Biotech Limited held its 16th Annual General Meeting on July 29, 2026, through video conferencing. The meeting was attended by 60449 shareholders. The company received, considered, and adopted the audited financial statements for the year ended March 31, 2026. The meeting also re-appointed a director in place of Mr. Gursimran Singh, who retires by rotation. The company also increased its authorized share capital and issued equity shares on a preferential basis.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange regarding the undertaking of its functional website, as per Reg. 46 of SEBI (LODR) Regulations, 2015.
Ajooni Biotech Limited
Ajooni Biotech Limited has submitted a Confirmation Certificate as per Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the Quarter Ended on 30th June, 2026.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 29, 2026, to consider increasing authorized share capital and issuance of equity shares on a preferential basis.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange regarding 'Intimation of Book Closure for the purpose of Annual General Meeting'. The Register of Member and Share Transfer Books will remain closed from July 23 to July 29, 2026, for taking record of members for the 16th Annual General Meeting to be held on July 17, 2026.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, increasing the authorized share capital and altering the capital clause of the Memorandum of Association, subject to shareholder approval in the AGM on July 29, 2026.
Ajooni Biotech Limited
Ajooni Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 29, 2026, where the Board decided to increase the Authorized Share Capital, issue preferential shares, and other matters.
Ajooni Biotech Limited
Ajooni Biotech Limited has announced the closure of its trading window for designated persons and employees, effective from July 01, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, in anticipation of the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The trading window will remain closed until 48 hours after the financial results are made public to the stock exchanges.